Shots:

• Valneva to receive $308M in cash including $130M up front- $35M as development milestones and $143M as early commercialization milestones and will fund 30% of all development costs through completion of the development program while in exchange Pfizer will pay Valneva royalties starting at 19%
• Pfizer will lead the late stage development of VLA15 and will be solely responsible for its commercialization. VLA15 revealed strong immunogenicity and safety data in pre-clinical and P-I studies while the company has completed the patient enrolment and follow-up for two P-II studies in 800+ people with anticipated results of first P-I study in mid-2020
• VLA15 is a multivalent protein subunit vaccine targeting OspA of Borrelia and covers six serotypes that are prevalent in North America and EU

Click here to­ read full press release/ article | Ref: Pfizer | Image: Telegraph India